Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Summary

Study TLK199.2107 is a multicenter, single arm, open-label Phase 2 study of oral ezatiostat (Telintra®) in patients with lenalidomide (Revlimid®) refractory or resistant, red blood cell (RBC) transfusion-dependent, Low to Intermediate-1 IPSS risk, del5q Myelodysplastic Syndrome (MDS).

Timeline

Start

2011-10

Primary completion

2013-02

Completion

2013-02

Outcome

Outcome not reported

Stopped (Business): “Study TLK199.2107 was terminated for business reasons.”

Drugs

Indications